Solventum Reports $8.3 Billion in 2024 Sales and Issues 2025 Shareholder Letter Ahead of Annual Meeting
SHERIDAN, WYOMING - April 14, 2026 - Solventum Corporation, the healthcare technology and medical products company spun out from 3M with over 70 years of healthcare innovation behind it, has issued its 2025 Year-End Shareholder Letter and reported full-year financial results that reflect $8.3 billion in 2024 sales and a workforce exceeding 20,000 professionals. The company's Q4 2025 earnings, released April 14, 2026, were accompanied by full-year guidance for 2026, signaling a deliberate push to establish Solventum as an independent, growth-oriented healthcare enterprise. The shareholder letter and earnings release collectively define a company in active transformation, managing a broad portfolio spanning medical devices, oral care, health IT, and purification and filtration technologies.